Xenon Pharmaceuticals (XENE) vs. Its Peers Head-To-Head Review

Xenon Pharmaceuticals (NASDAQ: XENE) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Xenon Pharmaceuticals to similar companies based on the strength of its dividends, earnings, risk, valuation, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Xenon Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals’ peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.


This table compares Xenon Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenon Pharmaceuticals -3,489.63% -47.53% -44.74%
Xenon Pharmaceuticals Competitors -5,528.73% -454.96% -42.61%

Valuation and Earnings

This table compares Xenon Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Xenon Pharmaceuticals $819,999.00 -$28.01 million -1.87
Xenon Pharmaceuticals Competitors $258.58 million $65.85 million -7.26

Xenon Pharmaceuticals’ peers have higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

55.3% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 9.4% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Xenon Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenon Pharmaceuticals 0 0 4 0 3.00
Xenon Pharmaceuticals Competitors 741 2976 11076 223 2.72

Xenon Pharmaceuticals currently has a consensus price target of $10.63, indicating a potential upside of 240.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.01%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than its peers.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply